Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

British Journal of Cancer

Volumn 73, Issue 2, 1996, Pages 228-235

  Modjtahedi, H ^a   Hickish, T ^b   Nicolson, M ^b   Moore, J ^b   Styles, J ^a   Eccles, S ^a   Jackson, E ^a   Salter, J ^b,c   Sloane, J ^b,c   Spencer, L ^b   Priest, K ^b   Smith, I ^b   Dean, C ^a   Gore, M ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c McElwain Laboratories ^*

Author keywords

Epidermal growth factor receptor; Monoclonal antibody; Phase I trial; Squamous cell carcinoma; Tumour localisation

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CHLORPHENIRAMINE MALEATE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROCORTISONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ICR 62; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CELL GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; FEMALE; FEVER; GROWTH INHIBITION; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR BINDING; RIGOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR LOCALIZATION; XENOGRAFT;

EID: 8944263458     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.40     Document Type: Article

References (42)

1. AARONSON SA. (1991). Growth factors and cancer. Science, 254, 1146-1153.
2. BASELGA J AND MENDELSOHN J. (1994). The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res. Treat., 29, 127-138.
3. 111Indium. Proc. Ann. Meet. Am. Soc. Clin. Oncol., 12, A368.
4. BILZER T, STASSIECKI P, VEGA F, KEMSBEAD JT, WESTPHAL M, SSHNUM E AND WECHSLER W. (1993). Immunotherapy of malignant gliomas with the anti-EGFR monoclonal antibody. Proc. Ann. Meet. Am. Assoc. Cancer Res., 34, A2877.
5. BRADY LW, MIYAMOTO C, WOO DV, RACKOVER M, EMRICH J, BENDER H, DADPARVAR S, STEPLEWSKI Z, KAPROWSKI H, BLACK P, LAZZARO B, NAIR S, MCCOROMACK T, NIEVES J, MARABITO M AND ESHLWMAN J. (1991). Malignant astrocytomas treated with iodine-125 labelled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int. J. Radiat. Oncol. Biol. Phys., 22, 225-230.
6. CARPENTER G. (1987). Receptor for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem., 56, 881-914.
7. COHEN S. (1962). Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J. Biol. Chem., 237, 1555-1562.
8. COWLEY G, SMITH JA AND GUSTERSON B. (1984). The amount of EGF receptor is elevated on squamous cell carcinomas. Cancer Cells, 1, 5-10.
9. CROSS M AND DEXTER TM. (1991). Growth factors in development, transformation, and tumorigenesis. Cell, 64, 271-280.
10. DADPARVAR S, KRISHNA L, MIYAMOTO C, BRADY LW, BROWN SJ, BENDER H, SLIZOFSKI WJ, CHEVRES A AND WOO DV. (1994). Indium-111-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas. Cancer Suppl., 73, 884-889.
11. DAS M, MIKYAWA T, FOX CF, PRUSS RM, AHARONOV A AND HERSHAMAN HR. (1977). Specific radiolabelling of cell surface receptor for EGF. Proc. Natl Acad. Sci. USA, 74, 2790-2794.
12. DEAN CJ, MODJTAHEDI H, ECCLES SA, BOX G AND STYLES JM. (1994). Immunotherapy with antibodies to the EGF receptor. Int. J. Cancer, 8, 103-107.
13. DERYNCK R. (1992). The physiology of transforming growth factor α. Adv. Cancer Res., 58, 27-52.
14. DIVIGI CR, WEST S, KRIS M, REAL FX, YEH DJ, GRALLA R, MERCHANT B, SCHWEIGHT S, UNGER M, LARSON SM AND MENDELSOHN J. (1991). Phase I and imaging trial of Indium III-labelled anti-EGF receptor antibody 225 in patients with squamous cell lung carcinomas. J. Natl Cancer Inst., 83, 97-104.
15. GOUSTIN AS, LEOF EB, SHIPLEY GD AND MOSES H. (1986). Growth factors and cancer. Cancer Res., 46, 1015-1029.
16. GULLICK WJ. (1991). Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull., 47, 87-98.
17. HARRIS AL. (1994). What is the biological, prognostic, and therapeutic role of the EGF receptor in human breast cancer? Breast Cancer Res. Treat., 29, 1-2.
18. HIGASHIYAMA S, ABRAHAM JA AND MILLER J. (1991). A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science, 257, 936-939.
19. KALOFONOS HP, PAWLIKOWSKA TR, HEMINGWAY A, COURTNAY-LUCK N, DHOKIA B, SNOOK D, SIVALAPENKO GB, HOOKER JR, MCKENZIE CG, LAVENDER PJ, THOMAS DCT AND EPENETOS AA. (1989). Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J. Nucl. Med., 30, 1636-1645.
20. MAGDELENAT H, DELATTRE JY, MADY E, FAOLLOT T, VEGA F AND POISSON M. (1991). A phase I study of the anti-EGFR monoclonal antibody 425 in patients with malignant gliomas. J. Tumor Marker Oncol., 6(4), 60.
21. MENDELSOHN J AND LIPPMAN, ME. (1993). Principles of molecular cell biology of cancer: Growth factors. In Cancer: Principles & Practice of Oncology, DeVita Jr VT, Hellman S and Rosenberg SA (eds) pp 114-133. JB Lippincott: Philadelphia.
22. MODJTAHEDI H AND DEAN CJ. (1994). The receptor for EGF and its ligands: Expression prognostic value and target for therapy in cancer (review). Int. J. Oncol., 4, 277-296.
23. MODJTAHEDI H AND DEAN C. (1995). The binding of HG-EGF to tumour cells is blocked by MAbs which act as EGF and TGFα antagonists. Biochem. Biophys. Res. Commun., 207, 389-397.
24. MODJTAHEDI H, STYLES JM AND DEAN CJ. (1993a). The human EGF receptor as a target for cancer therapy: six new rat MAbs against the receptor on the breast carcinoma MDA-MB 468. Br. J. Cancer, 67, 247-253.
25. MODJTAHEDI H, ECCLES SA, BOX G, STYLES JM AND DEAN CJ. (1993b). Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br. J. Cancer, 67, 254-261.
26. MODJTAHEDI H, ECCLES SA, SANDLE J, BOX G, TITLEY J AND DEAN CJ. (1994). Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res., 54, 1695-1701.
27. MODJTAHEDI H, JACKSON E AND DEAN C. (1995). Monovalent antibodies to the EGF receptor. Effects on proliferation and differentiation of tumours overexpressing the EGF receptor. Tumour Targeting, 1, 99-106.
28. NEAL DE, SHARPLES L AND SMITH K. (1990). The epidermal growth factor and the prognosis of bladder cancer. Cancer, 65, 1619-1625.
29. NICOLSON GL. (1993). Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp. Cell Res., 204, 171-180.
30. OZANNE BW, RICHARDS CS, HENDELER F, BURNS D AND GUSTERSON B. (1986). Overexpression of the EGF receptor is a hallmark of squamous cell carcinomas. J. Pathol., 149, 9-14. 1.
31. PEREZ-SOLER R, DONATO NJ, SHIN DM, ROSENBLUM MG, ZHANG HU, TORNOS G, BREWER H, CHANG JC, LEE JS, HONG WK AND MURRAY JL. (1994). Tumour epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J. Clin. Oncol., 12, 730-739.
32. PUSZTAI L, LEWIS CE, LORENZEN J AND MCGEE OD. (1993). Growth factors: regulation of normal and neoplastic growth. J. Pathol., 169, 191-201.
33. RIETHMULLER G, SCHNEIDER-GADICKE E, SCHLIMOK G, SCHMIEGEL W, RAAB R, HÖFFKEN K, GRUBER R, PICHLMAIER H, HIRCHE H, PICHLMAYR R, BUGGISCH P, WITTE J AND the German Cancer Aid 17-1A Study Group (1994). Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes's colorectal carcinoma. Lancet, 343, 1177-1183.
34. SHING Y, CHRISTOFORI G AND HANAHAN D. (1993). Betacellulin: a mitogen from pancreatic β cell tumors. Science, 259, 1604-1607.
35. SHOYAB M, PLOWMAN GD AND MCDONALD VL. (1989). Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science, 243, 1074-1076.
36. SOO KC, WARD M, ROBERTS KR, KEELING F, CARTER RL, MCREADY VR, OTT RJ, POWELL E, OZANNE B, WESTWOOD JH AND GUSTERSON BA. (1987). Radioimmunoscintigraphy of squamous carcinomas of the head and neck. Head and Neck Surgery, 9, 349-352.
37. SPORN MB AND ROBERTS AB. (1985). Autocrine growth factors and cancers. Nature, 313, 745-747.
38. STASIECKI P, KEMSHEAD JT, WESTPHAL, M, DELATTRE JY, GROPP P AND SIMANE Z (1993). The development of HAMA in glioma patients can be suppressed by administration of murine MAb in short time intervals. Proc. Ann. Meet. Am. Assoc. Cancer Res., 34, A2835.
39. THOMPSON DM AND GILL GN. (1985). The EGF receptor: Structure regulation and potential role in malignancy. Cancer Surveys, 4, 767-788.
40. TODARO GJ, DE LARCO JE AND COHEN S. (1976). Transformation by murine and feline sarcoma viruses specifically blocks binding of epidermal growth factor to cells. Nature, 264, 26-31.
41. VAN DE VIJVERT M, KUMAR R AND MENDELSOHN J. (1991). Ligand-induced activation of A431 cell epidermal growth factor occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J. Biol Chem., 266, 7503-7508.
42. WATERFIELD MD. (1991). The role of growth factors in cancer. In Introduction to the Cellular & Molecular Biology of Cancer, second edn Franks LM and Teich NM (eds) pp. 296-329. Oxford University Press: Oxford.